Bipolar Depression - Pipeline Insight, 2025

This “Bipolar Depression - Pipeline Insight, 2025” report provides comprehensive insights about 8+ companies and 10+ pipeline drugs in Bipolar Depression pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Bipolar Depression: Understanding

Bipolar Depression: Overview

Bipolar depression is a phase of bipolar disorder characterized by periods of depressive episodes, distinct from the manic or hypomanic phases of the disorder. Bipolar disorder is a chronic mental health condition that involves extreme mood swings, including emotional highs (mania or hypomania) and lows (depression). During a depressive episode, individuals experience intense sadness, hopelessness, and a lack of interest or pleasure in most activities. These episodes can severely impair daily functioning and quality of life. Signs and symptoms of bipolar depression include persistent feelings of sadness or emptiness, fatigue, and a significant decrease in energy. Individuals may experience sleep disturbances, changes in appetite or weight, difficulty concentrating, and feelings of worthlessness or excessive guilt. Suicidal thoughts or behaviors are also a critical concern during depressive episodes. Unlike unipolar depression, bipolar depression may present with psychomotor retardation, a symptom where a person's physical movements and thoughts slow down significantly.

The causes and pathophysiology of bipolar depression are multifaceted, involving a combination of genetic, neurobiological, and environmental factors. Genetic predisposition plays a significant role, with a higher likelihood of developing the disorder if a first-degree relative has it. Neurobiological factors include imbalances in neurotransmitters such as serotonin, norepinephrine, and dopamine, which regulate mood. Structural and functional brain abnormalities, particularly in areas like the prefrontal cortex and limbic system, are also implicated. Environmental stressors, such as trauma or significant life changes, can trigger or exacerbate bipolar episodes. Diagnosis of bipolar depression involves a comprehensive evaluation by a mental health professional, including a detailed psychiatric history and clinical assessment. The Diagnostic and Statistical Manual of Mental Disorders (DSM-5) criteria are used to identify the specific patterns of mood episodes. Differential diagnosis is crucial to distinguish bipolar depression from major depressive disorder and other psychiatric conditions. Often, collateral information from family or close associates is gathered to provide a complete picture of the individual's mood fluctuations over time.

Treatment for bipolar depression is multifaceted and often involves a combination of medication and psychotherapy. Mood stabilizers, such as lithium, and certain anticonvulsants are commonly used to manage mood swings. Antidepressants may be prescribed cautiously due to the risk of triggering manic episodes. Atypical antipsychotics can also be beneficial. Psychotherapy, particularly cognitive-behavioral therapy (CBT) and interpersonal and social rhythm therapy (IPSRT), helps individuals develop coping strategies, maintain regular daily routines, and improve their interpersonal relationships. In some cases, electroconvulsive therapy (ECT) may be considered for severe or treatment-resistant bipolar depression. Managing bipolar depression requires a long-term treatment plan and close monitoring to ensure stability and mitigate the risk of relapse.

'Bipolar Depression - Pipeline Insight, 2025' report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Bipolar Depression pipeline landscape is provided which includes the disease overview and Bipolar Depression treatment guidelines. The assessment part of the report embraces, in depth Bipolar Depression commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Bipolar Depression collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Bipolar Depression R&D. The therapies under development are focused on novel approaches to treat/improve Bipolar Depression.

Bipolar Depression Emerging Drugs Chapters

This segment of the Bipolar Depression report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Bipolar Depression Emerging Drugs

NRX-100/NRX-101: NRx Pharmaceuticals, Inc.

NRX-101 is a fixed-dose combination of D-Cycloserine and Lurasidone. NRX-101 is part of NRx Pharma’s investigational medicine regimen of NRX-100 (ketamine) and NRX-101. If approved by the U.S. Food and Drug Administration (FDA) and other health-regulatory agencies, would be the first medicine regimen to treat Severe Bipolar Depression in Patients with Acute Suicidal Ideation and Behavior (ASIB). NRX-101 is a patented, oral fixed-dose combination of two FDA-approved drugs: D-cycloserine, an NMDA receptor modulator at certain dosage ranges; and Lurasidone, a 5-HT2a receptor antagonist. The FDA has granted the combination therapy a Breakthrough Therapy Designation (BTD) for the treatment of severe bipolar depression in patients with acute suicidal ideation and behavior (ASIB), after initial stabilization with ketamine or other effective therapy. Currently the drug is in Phase III trial for Bipolar Depression.

ABX-002: Autobahn Therapeutics

ABX-002 is a potent and selective, brain-boosting TRβ agonist that is anticipated to enhance serotonin activity and elicit a brain bioenergetic effect in the brains of people suffering from MDD. Evidence suggests that a brain-targeted thyromimetic such as ABX-002 may, in a more selective fashion, evoke favorable thyroid hormone pharmacology in the CNS, while simultaneously eliminating the peripherally-mediated side effects of synthetic thyroid hormone (i.e., cardiac effects and effects on the thyroid hormone axis). Currently, the drug is in Phase II stage of its development for the treatment of Bipolar Depression.

Bipolar Depression: Therapeutic Assessment

This segment of the report provides insights about the different Bipolar Depression drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Bipolar Depression

• There are approx. 8+ key companies which are developing the therapies for Bipolar Depression. The companies which have their Bipolar Depression drug candidates in the most advanced stage, i.e. phase III include, NRx Pharmaceuticals, Inc.

Phases

The report covers around 10+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Bipolar Depression pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Molecule Type

Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Bipolar Depression: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Bipolar Depression therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Bipolar Depression drugs.

Bipolar Depression Report Insights

• Bipolar Depression Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Bipolar Depression Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Bipolar Depression drugs?
• How many Bipolar Depression drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Bipolar Depression?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Bipolar Depression therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Bipolar Depression and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• NRx Pharmaceuticals, Inc.

Autobahn Therapeutics

• Sunovion Pharmaceuticals Inc

Key Products

• NRX-100/NRX-101
• ABX-002
• DSP-3456

This product will be delivered within 2 business days.